March 26, 2013
/PRNewswire/ -- GlaxoSmithKline plc (GSK) and The
Texas A&M University
System announced today that the U.S. Department of Health and Human Services (DHHS) has approved the establishment of a
influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in
Bryan-College Station, Texas
The announcement was hosted by Governor
at the Texas State Capitol, and was attended by a number of dignitaries including Texas A&M System Chancellor
, DHHS Deputy Assistant Secretary and Director of the Biomedical Advanced Research and Development Authority (BARDA), and
, Senior Vice President, GSK Vaccines.
"Today's announcement is a huge win for
and for the nation," Governor Perry said. "The Texas A&M Center, anchored by this facility, is expected to bring more than
in expenditures within the
State of Texas
over the next 25 years, and will add more than 6,800 direct and related jobs to
The TAMUS influenza vaccines manufacturing center will afford GSK the capabilities to eventually manufacture influenza vaccine based on a proprietary cell-culture line, EB66®. Most existing influenza vaccine is manufactured using fertilized chicken eggs. The cell-culture process will supplement the vaccine supply from eggs, and facilitate a rapid national vaccine response in the event of a pandemic.
GSK Vaccines produces 30 vaccines worldwide, eleven of which are licensed by the FDA. The Texas A&M-GSK venture will complement and support the company's existing influenza vaccines operations, based in
. GSK's operations hub in
will package, inspect and distribute influenza vaccine manufactured at the Texas A&M Center. In 2012, GSK provided more than 20 million flu shots for the U.S. market and recently became the first major U.S. vaccines provider to gain FDA-approval for a broader-protection, four-strain (quadrivalent) influenza vaccine shot that will be available in time for the 2013-14 flu season.
"GSK is privileged to deepen our commitment to U.S. public health, as part of this unprecedented public-private collaboration to protect against pandemics and bio-threats," noted Loomans. "In Texas A&M we have found a partner with a rich tradition of service, and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need."